AI is not only transforming information and manufacturing—it is profoundly reshaping health and nutrition. In the past, precision nutrition largely remained in theory and the lab: vast datasets on individual genetic differences, protein structures, and biomarkers made truly personalized nutrition costly and inefficient.

With rapid advances in AI algorithms and computing power, capabilities in data processing and pattern recognition have surged, making the real-world adoption of precision nutrition increasingly feasible:

-Milestones: What landmark AI breakthroughs have emerged over the past three years across genomics, proteomics, and nutritional science?

-Scale-up readiness: How far are we from large-scale adoption in terms of technology, cost, and consumer acceptance?

-Lowering the barrier: How can AI reduce the threshold for delivering customized nutrition plans?

-Looking to 2030: In which areas of health and nutrition is AI poised to drive disruptive change?

China is entering a high-growth phase of diabetes and glucose intolerance prevalence. By 2023, the number of diabetes patients had reached 233 million. Between 2005 and 2023, the age-standardized prevalence rate increased by nearly 50%, with a pronounced trend of younger onset.

Traditional “one-size-fits-all” interventions are showing diminishing effectiveness when faced with diverse populations and complex metabolic profiles. In response, personalized glucose management—integrating continuous glucose monitoring (CGM), dietary and nutrition algorithms, microbiome insights, genetic data, and lifestyle profiling—is emerging as the new frontier of precision diabetes care.

Public data shows that in 2023, China’s low-GI food market reached a sales value of around 130 billion RMB, and is projected to surpass 200 billion RMB by 2030. Retailers are actively joining the race, leveraging health-focused labels to strengthen their brand positioning in consumers’ minds.

At its core, the value of low-GI products lies in offering people with glucose-control needs the confidence to “eat without fear.”

In recent years, GLP-1 receptor agonists have ushered in a new era in obesity drug development. While much attention has been focused on GLP-1, a groundbreaking study from Dr. Jonathan Long’s team at Stanford University, published in Nature, has revealed a weight-regulation pathway independent of GLP-1 mechanisms.

This newly identified pathway is driven by taurine and its metabolite N-acetyltaurine, which modulate the enzyme PTER, thereby influencing appetite and energy balance.

Could taurine—a compound commonly found in energy drinks—become the foundation of a new frontier in weight management?

By the end of 2024, China’s population aged 60 and above had reached 310 million, marking the silver economy’s entry into an unprecedented golden era. Unlike the past, when the focus was primarily on extending lifespan, today’s consumers aspire to “not just live longer, but live better.” Under the concept of active aging, the silver economy’s audience is expanding to younger groups who value functional health, quality of life, and emotional fulfillment.

This shift not only represents a vast opportunity for the health and elderly care industries, but also signals the continuous emergence of new products, services, and lifestyle scenarios.

Chronic inflammation drives aging, but existing anti-inflammatory methods often weaken immune defenses. A Nature study by Harvard and Duke scientists identified WSTF protein as a precise target: it declines only in chronic inflammation, silences pro-inflammatory genes, and curbs pro-aging signals. This discovery offers new possibilities for anti-aging research and future precision nutrition and health solutions.

For decades, “eating less to live longer” has been a cornerstone of aging research, yet its molecular mechanism remained elusive. A Xiamen University team led by a CAS academician published two *Nature* papers identifying lithocholic acid (LCA)—a gut microbiota–derived bile acid—as a natural molecule that mimics calorie restriction. LCA activates the AMPK pathway and delays aging in multiple animal models: extending worm and fly lifespans, increasing mouse lifespan by \~5%, and improving muscle strength and metabolic vitality. This breakthrough not only fills a missing link in the “calorie restriction–longevity” chain but also offers a novel target for longevity therapeutics—pointing to the possibility of extending healthy lifespan without enduring hunger.

Creatine’s global rise illustrates how a niche functional ingredient can break out: originally focused on fitness and sports nutrition, it gained mass awareness through viral social media, especially TikTok, boosting category sales and brand penetration.

According to SPINS data for the 52 weeks ending December 29, 2024, total creatine supplement sales in the US reached $378 million, representing a 22% CAGR from 2023–2024, with gummies being the standout growing at 360% YOY $ growth.

In the probiotic world, Akkermansia muciniphila (AKK) has emerged as a hot “dark horse.” Beyond supporting gut barrier integrity and immune regulation, it shows transformative effects on metabolic health, weight management, and inflammation control. Multiple studies link AKK directly to reduced obesity and diabetes risk, earning it recognition as a next-generation probiotic.

On June 26, 2025, Danone made a major investment to acquire Belgium’s The Akkermansia Company, fast-tracking the commercial rollout of this star strain. From premium functional yogurts to precision nutrition packs and future personalized health solutions, AKK is moving from research papers straight into consumers’ carts. This represents not only a convergence of scientific innovation and capital strategy but also a potential starting point for the next wave of global gut health market growth.